US pharma major Eli Lilly is to buy the PI3Kα inhibitor program STX-478 from Scorpion Therapeutics, a private US biotech ...

Jiangsu Hengrui and Kailera reveal Phase II data for HRS9531, a GLP-1/GIP dual agonist showing 21.1% placebo-adjusted weight ...

The NIH introduces a policy requiring drugmakers using its patents to submit affordability plans, addressing concerns over ...

French immunotherapy company OSE Immunotherapeutics has appointed Dr Sonya Montgomery as chief development officer. She will ...

Chinese biopharma Hutchmed today announced that the supplemental New Drug Application for Orpathys (savolitinib) has been ...

Dyno Therapeutics, a privately-held US genetic technologies company applying AI to enable in vivo gene delivery, has ...

French independent pharma company Servier says it has appointed David Lee to its executive committee as executive vice ...

US fibrosis-focused drug developer Mediar Therapeutics has entered into global licensing agreement with US pharma major Eli ...

Medicines Discovery Catapult (MDC), the UK government-backed life sciences service dedicated to driving productivity and ...

California-based immunology start-up Ouro Medicines, which is developing immune reset therapeutics for people living with ...

US radiopharmaceuticals-focused Lantheus Holdings today announced a definitive agreement to acquire Life Molecular Imaging.

UK pharma major GSK is to acquire IDRx, a Boston, USA-based, clinical-stage biopharma developing precision therapeutics for ...